This study is testing a medication called Orforglipron in people who are overweight or have obesity and also suffer from osteoarthritis (OA) of the knee. Orforglipron is taken by mouth. Some participants will receive Orforglipron, while others will receive a placebo (an inactive pill that looks like the study drug). The main goal is to see if Orforglipron can reduce knee pain, as measured by a specific pain score (WOMAC Pain Subscale Score) over 72 weeks. You might be able to join if you are 18 or older, have a BMI of 27 or higher, have tried to lose weight unsuccessfully, and have knee OA with certain symptoms like morning stiffness or being over 50 years old. The study is currently unclear about its recruitment status and plans to enroll about 800 participants.

Study design

This interventional study will involve about 800 participants. It will compare the effects of Orforglipron to a placebo, both administered orally.

What's involved

Participation in the study will last about 74 weeks. The primary endpoint, knee pain, will be measured at the beginning and at Week 72.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for about 72 weeks to measure changes in knee pain.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.